Bhatia Smita, Armenian Saro H, Armstrong Gregory T, van Dulmen-den Broeder Eline, Hawkins Michael M, Kremer Leontien C M, Kuehni Claudia E, Olsen Jørgen H, Robison Leslie L, Hudson Melissa M
Smita Bhatia and Saro H. Armenian, City of Hope National Medical Center, Duarte, CA; Gregory T. Armstrong, Leslie L. Robison, and Melissa M. Hudson, St Jude Children's Research Hospital, Memphis, TN; Eline van Dulmen-den Broeder, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Leontien C.M. Kremer, Academic Medical Center, Amsterdam, the Netherlands; Michael M. Hawkins, University of Birmingham, Birmingham, United Kingdom; Claudia E. Kuehni, University of Bern, Bern, Switzerland; and Jørgen H. Olsen, Danish Cancer Society Research Center, Copenhagen, Denmark.
J Clin Oncol. 2015 Sep 20;33(27):3055-64. doi: 10.1200/JCO.2014.59.8052. Epub 2015 Aug 24.
Survivors of childhood cancer carry a substantial burden of morbidity and are at increased risk for premature death. Furthermore, clear associations exist between specific therapeutic exposures and the risk for a variety of long-term complications. The entire landscape of health issues encountered for decades after successful completion of treatment is currently being explored in various collaborative research settings. These settings include large population-based or multi-institutional cohorts and single-institution studies. The ascertainment of outcomes has depended on self-reporting, linkage to registries, or clinical assessments. Survivorship research in the cooperative group setting, such as the Children's Oncology Group, has leveraged the clinical trials infrastructure to explore the molecular underpinnings of treatment-related adverse events, and to understand specific complications in the setting of randomized risk-reduction strategies. This review highlights the salient findings from these large collaborative initiatives, emphasizing the need for life-long follow-up of survivors of childhood cancer, and describing the development of several guidelines and efforts toward harmonization. Finally, the review reinforces the need to identify populations at highest risk, facilitating the development of risk prediction models that would allow for targeted interventions across the entire trajectory of survivorship.
儿童癌症幸存者承受着巨大的发病负担,过早死亡风险也有所增加。此外,特定治疗暴露与多种长期并发症风险之间存在明确关联。目前正在各种协作研究环境中探索成功完成治疗数十年后所遇到的健康问题全貌。这些环境包括基于人群的大型队列或多机构队列以及单机构研究。结局的确定依赖于自我报告、与登记处的关联或临床评估。在合作组环境中的生存研究,如儿童肿瘤组,利用临床试验基础设施来探索治疗相关不良事件的分子基础,并了解随机风险降低策略背景下的特定并发症。本综述重点介绍了这些大型协作倡议的显著发现,强调了对儿童癌症幸存者进行终身随访的必要性,并描述了若干指南的制定以及协调方面的努力。最后,该综述强调了识别高危人群的必要性,以促进风险预测模型的开发,从而能够在整个生存轨迹中进行有针对性的干预。